Literature DB >> 18713954

Neural control of the anorexia-cachexia syndrome.

Alessandro Laviano1, Akio Inui, Daniel L Marks, Michael M Meguid, Claude Pichard, Filippo Rossi Fanelli, Marilia Seelaender.   

Abstract

The anorexia-cachexia syndrome is a debilitating clinical condition characterizing the course of chronic diseases, which heavily impacts on patients' morbidity and quality of life, ultimately accelerating death. The pathogenesis is multifactorial and reflects the complexity and redundancy of the mechanisms controlling energy homeostasis under physiological conditions. Accumulating evidence indicates that, during disease, disturbances of the hypothalamic pathways controlling energy homeostasis occur, leading to profound metabolic changes in peripheral tissues. In particular, the hypothalamic melanocortin system does not respond appropriately to peripheral inputs, and its activity is diverted largely toward the promotion of catabolic stimuli (i.e., reduced energy intake, increased energy expenditure, possibly increased muscle proteolysis, and adipose tissue loss). Hypothalamic proinflammatory cytokines and serotonin, among other factors, are key in triggering hypothalamic resistance. These catabolic effects represent the central response to peripheral challenges (i.e., growing tumor, renal, cardiac failure, disrupted hepatic metabolism) that are likely sensed by the brain through the vagus nerve. Also, disease-induced changes in fatty acid oxidation within hypothalamic neurons may contribute to the dysfunction of the hypothalamic melanocortin system. Ultimately, sympathetic outflow mediates, at least in part, the metabolic changes in peripheral tissues. Other factors are likely involved in the pathogenesis of the anorexia-cachexia syndrome, and their role is currently being elucidated. However, available evidence shows that the constellation of symptoms characterizing this syndrome should be considered, at least in part, as different phenotypes of common neurochemical/metabolic alterations in the presence of a chronic inflammatory state.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713954     DOI: 10.1152/ajpendo.90252.2008

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  35 in total

Review 1.  Brain-immune interactions and the neural basis of disease-avoidant ingestive behaviour.

Authors:  Gustavo Pacheco-López; Federico Bermúdez-Rattoni
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-12-12       Impact factor: 6.237

2.  The interaction between pro-inflammatory cytokines and the nervous system.

Authors:  Alessio Molfino; Filippo Rossi-Fanelli; Alessandro Laviano
Journal:  Nat Rev Cancer       Date:  2009-02-05       Impact factor: 60.716

3.  Anorexia: an early sign of fourth ventricle astrocytoma in children.

Authors:  Henri-Arthur Leroy; Marc Baroncini; Isabelle Delestret; Vincent Florent; Matthieu Vinchon
Journal:  Childs Nerv Syst       Date:  2014-08-21       Impact factor: 1.475

4.  A Phase II dose titration study of thalidomide for cancer-associated anorexia.

Authors:  Mellar Davis; Wael Lasheen; Declan Walsh; Fade Mahmoud; Leslie Bicanovsky; Ruth Lagman
Journal:  J Pain Symptom Manage       Date:  2011-06-02       Impact factor: 3.612

Review 5.  Disease specific substrates in cancer cachexia - Reality and anticipation.

Authors:  Zdeněk Zadák; Alena Tichá; Radomír Hyšpler
Journal:  Rep Pract Oncol Radiother       Date:  2012-12-05

Review 6.  Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?

Authors:  Mark D DeBoer
Journal:  Mol Cell Endocrinol       Date:  2011-02-25       Impact factor: 4.102

Review 7.  Melanocortin control of energy balance: evidence from rodent models.

Authors:  Bart C De Jonghe; Matthew R Hayes; Kendra K Bence
Journal:  Cell Mol Life Sci       Date:  2011-05-08       Impact factor: 9.261

Review 8.  Sarcopenia in cases of chronic and acute illness. A mini-review.

Authors:  Peter Dovjak
Journal:  Z Gerontol Geriatr       Date:  2015-11-26       Impact factor: 1.281

9.  Chronic renal failure, cachexia, and ghrelin.

Authors:  A Laviano; Z Krznaric; K Sanchez-Lara; I Preziosa; A Cascino; F Rossi Fanelli
Journal:  Int J Pept       Date:  2010-02-04

10.  Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopolysaccharide-induced cachexia in rats.

Authors:  Jean-Christophe Peter; Hélène Rossez; Marjorie Weckering; Géraldine Zipfel; Anne-Catherine Lecourt; Joshua B Owen; William A Banks; Karl G Hofbauer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-08-22       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.